Störungen von Affekt und Kognition bei Patienten mit Multipler Sklerose

F. Weber

doi:10.1055/s-0038-1626281

Nervenheilkunde, Table of Contents

Nervenheilkunde 2004; 23(02): 94-98
DOI: 10.1055/s-0038-1626281

Original- und Übersichtsarbeiten - Original and Review Articles

Schattauer GmbH

Störungen von Affekt und Kognition bei Patienten mit Multipler Sklerose

Impairment of affect and cognition in patients with multiple sclerosis

F. Weber

¹Max-Planck-Institut für Psychiatrie, München

› Author Affiliations

Abstract

Zusammenfassung

Depression, Fatigue und Kognitionsstörungen sind Symptome der Multiplen Sklerose (MS), die oft bereits zu Beginn der Erkrankung auftreten und die Lebensqualität der MS-Patienten erheblich beeinträchtigen können. Während die Pathogenese von Depression und Fatigue weiterhin ungeklärt ist, zeigen die Kognitionsstörungen eine gute Korrelation mit der zerebralen Atrophie. Mehrere Studien und die klinische Erfahrung belegen die Wirksamkeit von Antidepressiva bei MS-Patienten mit Depression sowie von Amantadin und Modafinil bei Fatigue. Die immunmodulatorische Therapie mit Interferon-ß (IFN-ß) kann die Progredienz der zerebralen Atrophie und der kognitiven Defizite verlangsamen. Weiterhin weist eine Studie darauf hin, dass auch Acetylcholinesterasehemmer wirksam sein könnten. Entsprechend ihrer Bedeutung für die Lebensqualität der Patienten sollten Depression, Fatigue und kognitive Störungen bei der Behandlung und Erforschung der MS stärkere Berücksichtigung finden.

Summary

Depression, fatigue and cognitive impairment are common symptoms of patients with multiple sclerosis (MS), which frequently occur early in the disease course and exert a strong impact on quality of life. While the pathogenesis of depression and fatigue is still unknown, cognitive impairment correlates well with cerebral atrophy. Clinical experience and a few studies demonstrate the effectiveness of antidepressants in MS patients with depression and of amantadine and modafinil in MS patients with fatigue. The immunomodulatory therapy with interferon-ß (IFN-ß) slows the progression of cerebral atrophy and cognitive impairment. In addition one study indicates, that acetylcholinesterase inhibitors may be effective. According to their importance in everyday life depression, fatigue and cognitive deficits should be considered more adequately in research and therapeutic approaches.

Schlüsselwörter

Multiple Sklerose - Depression - Fatigue - kognitive Störungen

Keywords

Multiple sclerosis - depression - fatigue - cognitive impairment

Full Text

References

Literatur
1 Amato MP, Ponziani G, Pracucci G, Bracco L, Siracusa G, Amaducci L. Cognitive impairment in early-onset multiple sclerosis. Pattern, predictors, and impact on everyday life in a 4-year follow-up. Arch Neurol 1995; 52 (02) 168-72.
2 Bakshi R, Czarnecki D, Shaikh ZA, Priore RL, Janardhan V, Kaliszky Z, Kinkel PR. Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport 2000; 11 (06) 1153-8.
3 Barak Y, Achiron A. Effect of Interferonbeta-1b on Cognitive Functions in Multiple Sclerosis. Eur Neurol 2002; 47 (01) 11-4.
4 Barak Y, Ur E, Achiron A. Moclobemide treatment in multiple sclerosis patients with comorbid depression: an open-label safety trial. J Neuropsychiatry Clin Neurosci 1999; 11 (02) 271-3.
5 Berg D, Supprian T, Thomae J, Warmuth-Metz M, Horowski A, Zeiler B, Magnus T, Rieckmann P, Becker G. Lesion pattern in patients with multiple sclerosis and depression. Mult Scler 2000; 06 (03) 156-62.
6 Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci 1987; 14 (03) 273-8.
7 European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352 9139 1491-7.
8 Feinstein A, O’Connor P, Feinstein K. Multiple sclerosis, interferon beta-1b and depression A prospective investigation. J Neurol 2002; 249 (07) 815-20.
9 Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology 2002; 59 (05) 674-8.
10 Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Goodkin DE, Granger CV, Simon JH, Grafman JH, Lezak MD, O’Reilly KMHovey, Perkins KK, Barilla-Clark D, Schacter M, Shucard DW, Davidson AL, Wende KE, Bourdette DN, Kooijmans-Coutinho MF. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000; 48 (06) 885-92.
11 Flachenecker P, Kümpfel T, Kallmann B, Gottschalk M, Grauer O, Rieckmann P, Trenkwalder C, Toyka KV. Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler 2002; 08 (06) 523-6.
12 Ge Y, Grossman RI, Udupa JK, Fulton J, Constantinescu CS, Gonzales-Scarano F, Babb JS, Mannon LJ, Kolson DL, Cohen JA. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology 2000; 54 (04) 813-7.
13 Greene YM, Tariot PN, Wishart H, Cox C, Holt CJ, Schwid S, Noviasky J. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol 2000; 20 (03) 350-6.
14 Honer WG, Hurwitz T, Li DK, Palmer M, Paty DW. Temporal lobe involvement in multiple sclerosis patients with psychiatric disorders. Arch Neurol 1987; 44 (02) 187-90.
15 IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
16 Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343 (13) 898-904.
17 Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer 3rd FE, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH. et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
18 Kahl KG, Kruse N, Faller H, Weiss H, Rieckmann P. Expression of tumor necrosis factoralpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. Psychoneuroendocrinology 2002; 27 (06) 671-81.
19 Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L, Halper J, Johnson B, Morgante L, Grimson R. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995; 45 (11) 1956-61.
20 Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33 (11) 1444-52.
21 Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997; 54 (05) 531-3.
22 Murray TJ. Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci 1985; 12 (03) 251-254.
23 Patten SB, Metz LM. Interferon beta-1 a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler 2001; 07 (04) 243-8.
24 Patten SB, Metz LM. Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial. Neurology 2002; 59 (05) 744-6.
25 Pliskin NH, Hamer DP, Goldstein DS, Towle VL, Reder AT, Noronha A, Arnason BG. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 1996; 47 (06) 1463-8.
26 Plohmann AM, Kappos L, Ammann W, Thordai A, Wittwer A, Huber S, Bellaiche Y, Lechner-Scott J. Computer assisted retraining of attentional impairments in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64 (04) 455-62.
27 Polman CH, Bertelsmann FW, de Waal R, van Diemen HA, Uitdehaag BM, van Loenen AC, Koetsier JC. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis. Arch Neurol 1994; 51 (11) 1136-9.
28 Pujol J, Bello J, Deus J, Marti-Vilalta JL, Capdevila A. Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis. Neurology 1997; 49 (04) 1105-10.
29 Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002; 72 (02) 179-83.
30 Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain 2001; 124 (Pt 9): 1803-12.
31 Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsingremitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53 (08) 1698-1704.
32 Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991; 41 (08) 1193-6.
33 Sadovnick AD, Remick RA, Allen J, Swartz E, Yee IM, Eisen K, Farquhar R, Hashimoto SA, Hooge J, Kastrukoff LF, Morrison W, Nelson J, Oger J, Paty DW. Depression and multiple sclerosis. Neurology 1996; 46 (03) 628-32.
34 Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry 1990; 147 (11) 1493-7.
35 Scott TF, Nussbaum P, McConnell H, Brill P. Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale. Neurol Res 1995; 17 (06) 421-2.
36 Simon JH, Jacobs LD, Campion MK, Rudick RA, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Simonian N, Lajaunie M, Miller DE, Wende K, Martens-Davidson A, Kinkel RP, Munschauer 3rd FE, Brownscheidle CM. A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1999; 53 (01) 139-48.
37 Then FBergh, Kümpfel T, Grasser A, Rupprecht R, Holsboer F, Trenkwalder C. Combined treatment with corticosteroids and moclobemide favors normalization of hypothalamopituitary-adrenal axis dysregulation in relapsing-remitting multiple sclerosis: a randomized, double blind trial. J Clin Endocrinol Metab 2001; 86 (04) 1610-5.
38 Then FBergh, Kümpfel T, Trenkwalder C, Rupprecht R, Holsboer F. Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS. Neurology 1999; 53 (04) 772-7.
39 Weinshenker BG, Penman M, Bass B, Ebers GC, Rice GP. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 1992; 42 (08) 1468-71.
40 Weinstein A, Schwid SI, Schiffer RB, McDermott MP, Giang DW, Goodman AD. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999; 56 (03) 319-24.
41 Wells KB, Golding JM, Burnam MA. Psychiatric disorder in a sample of the general population with and without chronic medical conditions. Am J Psychiatry 1988; 145 (08) 976-81.
42 Wingerchuk DM, Scottsdale AZ, Benarroch EE, O´Brien PC, Keegan BM, Lucchinetti CF. et al. Aspirin for multiple sclerosis-related fatigue: results of a double-blind, placebocontrolled study. Neurology 2002; 58 (Suppl. 03) A 492.
43 Zimmermann C, Hohlfeld R. Fatigue in multiple sclerosis. Nervenarzt 1999; 70 (06) 566-74.
44 Zivadinov R, Sepcic J, Nasuelli D, De Masi R, Bragadin LM, Tommasi MA, Zambito-Marsala S, Moretti R, Bratina A, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 70 (06) 773-80.